Axon Enterprise, Inc. (NASDAQ:AXON) Director Sells $4,493,880.00 in Stock

Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) Director Michael Garnreiter sold 5,913 shares of Axon Enterprise stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total value of $4,493,880.00. Following the completion of the transaction, the director now owns 17,740 shares in the company, valued at $13,482,400. The trade was a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael Garnreiter also recently made the following trade(s):

• On Tuesday, June 3rd, Michael Garnreiter sold 87 shares of Axon Enterprise stock. The stock was sold at an average price of $760.00, for a total transaction of $66,120.00.

Axon Enterprise Stock Performance

Shares of AXON traded up $7.88 during trading hours on Friday, hitting $796.24. The company's stock had a trading volume of 210,754 shares, compared to its average volume of 729,301. Axon Enterprise, Inc. has a 52-week low of $278.24 and a 52-week high of $798.16. The business has a 50 day simple moving average of $638.88 and a two-hundred day simple moving average of $615.19. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The company has a market cap of $61.99 billion, a price-to-earnings ratio of 205.75, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The company's quarterly revenue was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.15 EPS. On average, equities analysts expect that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Barclays raised their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Needham & Company LLC lifted their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Bank of America upped their price target on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Finally, The Goldman Sachs Group raised their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Axon Enterprise has a consensus rating of "Moderate Buy" and a consensus price target of $699.55.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors have recently made changes to their positions in AXON. Brighton Jones LLC purchased a new position in shares of Axon Enterprise in the 4th quarter worth about $480,000. Caprock Group LLC bought a new stake in Axon Enterprise in the 4th quarter worth approximately $329,000. DAVENPORT & Co LLC boosted its stake in Axon Enterprise by 7.6% in the fourth quarter. DAVENPORT & Co LLC now owns 894 shares of the biotechnology company's stock worth $531,000 after buying an additional 63 shares in the last quarter. U.S. Capital Wealth Advisors LLC boosted its stake in Axon Enterprise by 53.2% in the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 2,032 shares of the biotechnology company's stock worth $1,208,000 after buying an additional 706 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC grew its position in Axon Enterprise by 74.1% during the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 40 shares during the last quarter. Institutional investors own 79.08% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.